Monsanto Co. v. Durnell, 609 U. S. ___ (2026): the Supreme Court holds that FIFRA expressly preempts a state failure-to-warn claim, and the ripple reaches workers' compensation.
On June 25, 2026, the United States Supreme Court decided Monsanto Co. v. Durnell, holding that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts a state-law failure-to-warn claim that would force a cancer warning onto Roundup's label. Writing for a seven-Justice majority, Justice Kavanaugh reversed a Missouri jury's award to John Durnell, a long-term Roundup user who developed non-Hodgkin's lymphoma. The decision is short on sympathy and long on consequences, and its logic extends well beyond herbicides, directly into the world of occupational disease and workers' compensation.
The Court's Rationale
The majority's reasoning rests on a chain of statutory steps. FIFRA's preemption clause, titled Uniformity, provides that a state “shall not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under” the statute. 7 U. S. C. §136v(b). The Court treated this as the decisive text, reasoning that uniformity in labeling would be impossible if fifty states could each demand their own warnings through tort verdicts.
To register a pesticide, the EPA must approve its label, confirming that the label carries every warning “necessary and . . . adequate to protect health and the environment” and that it contains no false or misleading statements. Once the EPA approves that label, the Court held, the manufacturer is legally required to use it and may not unilaterally change it, on pain of civil and criminal penalties. From that premise the majority drew its central conclusion: the EPA-approved Roundup label, sold for decades without a cancer warning, is itself a federal requirement. A jury verdict demanding a cancer warning therefore imposes a labeling rule “in addition to” and “different from” federal law, and is preempted.
The Court relied heavily on Riegel v. Medtronic, Inc., 552 U. S. 312 (2008), in which the FDA's premarket approval of a medical device was held to impose preemptive federal requirements under a nearly identical clause. If FDA approval counts, the majority reasoned, so must EPA registration. It distinguished Bates v. Dow Agrosciences LLC, 544 U. S. 431 (2005), as a case about efficacy claims the EPA never reviewed, while safety claims like Durnell's go to the heart of what the EPA does evaluate.
Justice Thomas concurred, questioning whether FIFRA exceeds the Commerce Clause and whether agency action can preempt state law at all. Justice Jackson, joined by Justice Gorsuch, dissented forcefully. She argued that registration is, by the statute's own terms in §136a(f)(2), only “prima facie” evidence of compliance, not conclusive proof, so an approved label cannot be a binding federal requirement. In her view, Durnell's claim merely paralleled FIFRA's own misbranding prohibition and should have survived, consistent with the near-unanimous weight of state and federal authority, including Hardeman v. Monsanto Co., 997 F. 3d 941 (CA9 2021).
Where Workers' Compensation Fits the Analysis
At first glance, Durnell is a products-liability case. But pesticides are quintessential occupational exposures. Agricultural laborers, landscapers, groundskeepers, golf-course and nursery workers, municipal road crews, and warehouse and applicator personnel handle glyphosate and dozens of other registered chemicals as a daily condition of employment. When those exposures produce disease, the first system most workers turn to is not a product suit but workers' compensation.
Workers' compensation and the third-party tort claim are companion remedies. The compensation system pays medical and indemnity benefits regardless of fault, but those benefits are capped, and the carrier or self-insured employer ordinarily holds a statutory lien or subrogation interest against any recovery the worker obtains from the chemical manufacturer. The third-party failure-to-warn suit is where the full measure of damages and the funds that reimburse the compensation carrier have traditionally come from. Durnell quietly removes that companion remedy for an entire category of registered pesticides.
The connection runs deeper. Failure-to-warn litigation has long functioned as an information-forcing mechanism, a point the dissent drew from Bates: tort suits act as a “catalyst” pushing manufacturers to keep labels current with emerging science. In occupational disease, where latency periods stretch across decades and regulatory science often lags the bedside, that catalyst matters. Asbestos, silica, benzene, and PFAS each tell the same story: the warnings that ultimately protected workers frequently arrived through litigation, not through the agency acting alone. Cutting off the pesticide failure-to-warn claim weakens one of the few levers that historically forced earlier, fuller disclosure of occupational hazards.
Impact on Injured Workers and Their Benefits
For the injured worker and the surviving family, the practical consequences of this decision are significant and largely adverse:
• Loss of the third-party recovery. A worker exposed to a registered pesticide on the job who develops cancer can no longer pursue a state failure-to-warn claim premised on the absence of a label warning. The largest source of compensation, the manufacturer suit, is closed.
• Heavier reliance on capped benefits. With the tort avenue foreclosed, the worker is left with workers' compensation alone, a system that limits indemnity rates, often undervalues latent occupational cancers, and may dispute causation aggressively where a chemical has an EPA registration suggesting it is “not likely” to cause cancer.
• Weakened carrier subrogation. Compensation carriers and self-insured employers that pay benefits up front rely on third-party recoveries to recoup their lien. Eliminating the manufacturer claim shifts the entire economic burden of occupational pesticide disease onto the compensation system and, ultimately, onto employers and the worker's own capped award.
• A causation shield for defendants. The same EPA registration the Court relied on can be marshaled by employers and carriers to contest occupational-causation in the compensation forum, even though Durnell technically decided only label preemption.
• Survivors left without a remedy. As the dissent put it, the decision “unjustifiably closes the courthouse doors” to plaintiffs like Durnell, and dependency claims for fatal occupational cancers lose their most meaningful path to full compensation.
The result is a quiet redistribution of risk. The cost of pesticide-related occupational disease is shifted from the manufacturer to the worker, the worker's family, and the compensation system, while the EPA's decades-old registration decision is treated as a near-conclusive answer to a scientific question that remains genuinely contested.
Should Congress Act
Yes. The preemption the Court found is statutory, not constitutional, which means Congress can fix it. Because Durnell turns entirely on how broadly the words “required under” §136v(b) are read, a modest amendment would restore the balance that most courts had struck for two decades.
A targeted legislative response could include:
• A savings clause confirming that FIFRA does not preempt state failure-to-warn claims that parallel the statute's own misbranding prohibition, codifying the Bates reading the dissent endorsed.
• Language clarifying that EPA registration and label approval are “prima facie” evidence of compliance, not a conclusive federal labeling requirement, consistent with the existing text of §136a(f)(2).
• An express preservation of workers' compensation and third-party occupational-disease remedies for exposures to registered pesticides, so that the compensation lien and the worker's recovery are not silently extinguished.
Congress has amended FIFRA before, in 1972 and again in 1988, precisely to recalibrate the federal-state balance. Restoring the injured worker's remedy for occupational pesticide disease is squarely within its power, and the families left without recourse after Durnell are a compelling reason to use it.
Until Congress acts, practitioners should assume that label-based failure-to-warn theories against registered-pesticide manufacturers face a steep preemption barrier, and should build occupational-exposure cases on the compensation record, alternative theories, and causation proof that does not depend on the absent label warning.
Sources
1. Monsanto Co. v. Durnell, 609 U. S. ___ (2026) (slip op.).
2. Bates v. Dow Agrosciences LLC, 544 U. S. 431 (2005).
3. Riegel v. Medtronic, Inc., 552 U. S. 312 (2008).
4. Cipollone v. Liggett Group, Inc., 505 U. S. 504 (1992).
5. Wisconsin Public Intervenor v. Mortier, 501 U. S. 597 (1991).
6. Medtronic, Inc. v. Lohr, 518 U. S. 470 (1996).
7. Wyeth v. Levine, 555 U. S. 555 (2009).
8. PLIVA, Inc. v. Mensing, 564 U. S. 604 (2011).
9. Mutual Pharmaceutical Co. v. Bartlett, 570 U. S. 472 (2013).
10. Murphy v. National Collegiate Athletic Assn., 584 U. S. 453 (2018).
11. United States v. Lopez, 514 U. S. 549 (1995).
12. Loper Bright Enterprises v. Raimondo, 603 U. S. 369 (2024).
13. Ruckelshaus v. Monsanto Co., 467 U. S. 986 (1984).
14. Hardeman v. Monsanto Co., 997 F. 3d 941 (9th Cir. 2021).
15. Boyle v. United Technologies Corp., 487 U. S. 500 (1988).
16. Federal Insecticide, Fungicide, and Rodenticide Act, 7 U. S. C. §136 et seq.
About the Author
Jon L. Gelman of Wayne, NJ is the author of NJ Workers' Compensation Law (West-Thomson-Reuters) and co-author of Modern Workers' Compensation Law (West-Thomson-Reuters).
Blog: Workers' Compensation | LinkedIn: JonGelman | Substack: jongelman.substack.com | Blue Sky: jongelman@bsky.social
© 2026 Jon L Gelman. All rights reserved. | Attorney Advertising | Prior results do not guarantee a similar outcome.
Disclaimer | Download Adobe Reader
No comments:
Post a Comment